Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.73 |
| ▸ | CA1 | P00915 | 7/20 | 0.73 |
| ▸ | CA9 | Q16790 | 7/20 | 0.73 |
| ▸ | CA12 | O43570 | 4/20 | 0.73 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.59 |
| ▸ | CA4 | P22748 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | TTK | P33981 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.50 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30646273 | 1.00 | CA2 (0.73) | CA2CA1CA9CA12CA14 | |
| SCHEMBL3151230 | 0.83 | MTNR1B (0.56) | CA2CA1CA9CA12FFAR4 | |
| SCHEMBL31352975 | 0.83 | MTNR1B (0.56) | CA2CA1CA9CA12FFAR4 | |
| SCHEMBL803706 | 0.82 | NFE2L2 (0.54) | CA2CA1CA9CA12FFAR4 | |
| SCHEMBL11155550 | 0.82 | NFE2L2 (0.54) | CA2CA1CA9CA12FFAR4 | |
| SCHEMBL29650302 | 0.82 | NFE2L2 (0.54) | CA2CA1CA9CA12FFAR4 | |
| SCHEMBL28110469 | 0.80 | CA9 (0.68) | CA2CA1CA9CA12CA4 | |
| SCHEMBL1299768 | 0.80 | NFE2L2 (0.53) | CA2CA1CA9CA12FFAR4 | |
| SCHEMBL4616965 | 0.80 | NFE2L2 (0.53) | CA2CA1CA9CA12FFAR4 | |
| SCHEMBL13290766 | 0.80 | NFE2L2 (0.53) | CA2CA1CA9CA12FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | claimed |
| CN-119233829-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy | 学校法人高崎健康福祉大学 | 2024-12-31 | — | — | CN | claimed |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-12-05 | — | — | US | claimed |
| CN-118176003-A | Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain | 日本化学药品株式会社 | 2024-06-11 | — | — | CN | claimed |
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| CN-118019551-A | Preventive or therapeutic agent for respiratory diseases | 日本化学药品株式会社 | 2024-05-10 | — | — | CN | claimed |
| CN-115942938-A | Medicine for preventing or treating irritable bowel syndrome or inflammatory bowel disease | 比萨大学 | 2023-04-07 | — | — | CN | claimed |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | claimed |
| EP-2616440-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | Adamed sp. z o.o. (PL) | 2013-07-24 | — | — | EP | claimed |
| WO-2012035123-A1 | ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES | ADAMED SP. Z O.O. (PL) | 2012-03-22 | — | — | WO | claimed |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | claimed |
| WO-2008100618-A2 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4709384-A2 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV Pharmaceuticals, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2003087061-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| US-20030105148-A1 | Selective estrogen receptor modulators | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-05 | — | — | US | disclosed |
| WO-2003016270-A2 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| US-4254260-A | 3-Substituted-7-substituted alkanamido-3-cephem-4-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105148-A1 | Selective estrogen receptor modulators | ESR1, GPER1, PTGIR | CA2 3557/4885CA1 2560/4885CA9 2343/4885 |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | CA2 413/4885CA1 573/4885CA9 1806/4885 |
| US-20240400591-A1 | COMPOUNDS TARGETING MUTANT OF P53 | TP53, TP53BP1, MDM2 | CA2 3601/4885CA1 2782/4885CA9 3658/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | CA2 743/4885CA1 3219/4885CA9 505/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | CA2 3533/4885CA1 1652/4885CA9 2219/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | CA2 2753/4885CA1 3047/4885CA9 2810/4885 |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | CA2 4235/4885CA1 4705/4885CA9 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.